<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496767</url>
  </required_header>
  <id_info>
    <org_study_id>CY 4031</org_study_id>
    <secondary_id>2014-005413-23</secondary_id>
    <nct_id>NCT02496767</nct_id>
  </id_info>
  <brief_title>Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year</brief_title>
  <acronym>VITALITY-ALS</acronym>
  <official_title>A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the effect of tirasemtiv versus placebo on respiratory function in
      patients with ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CY 4031 was a multi-national, double-blind, randomized, placebo-controlled, stratified,
      parallel group study of tirasemtiv in patients with ALS. The study had three phases: an
      open-label phase (2 weeks), a double-blind, placebo-controlled phase (48 weeks), and a
      double-blind, placebo-controlled tirasemtiv withdrawal phase (4 weeks). Patients who
      completed 2 weeks of treatment with open-label tirasemtiv (125 mg twice daily) were
      randomized 3:2:2:2 to placebo or one of three dose levels of tirasemtiv (250 mg/day, 375
      mg/day, or 500 mg/day). Approximately 600 patients were planned to be enrolled into the
      open-label treatment phase.

      Patients taking riluzole at study entry could continue use of riluzole during the study as
      long as they had been on a stable dose for at least 30 days prior to study screening. In
      addition, for patients randomized to tirasemtiv, the riluzole dose was reduced to half the
      approved dose (ie, reduced to 50 mg once daily) because administration of tirasemtiv
      approximately doubles the exposure to concomitant riluzole. Patients randomized to placebo
      continued riluzole at 50 mg twice daily. This was accomplished without unmasking the study's
      blind as follows:

        1. All patients on riluzole took their morning 50 mg dose of riluzole from their personal
           riluzole supply.

        2. The sponsor supplied the evening riluzole dose as double-blind study medication, as
           follows: (a) for patients randomized to placebo, the double-blind, evening riluzole dose
           was 50 mg of active riluzole; (b) for patients randomized to tirasemtiv, the
           double-blind, evening riluzole dose was a matching placebo for riluzole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2015</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)</measure>
    <time_frame>24 weeks</time_frame>
    <description>SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics [eg, height, age, sex], based on Knudson 83 normative values).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">744</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 250 mg tirasemtiv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - 375 mg tirasemtiv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - 500 mg tirasemtiv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirasemtiv</intervention_name>
    <arm_group_label>Group 2 - 250 mg tirasemtiv</arm_group_label>
    <arm_group_label>Group 3 - 375 mg tirasemtiv</arm_group_label>
    <arm_group_label>Group 4 - 500 mg tirasemtiv</arm_group_label>
    <other_name>CK-2017357</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <arm_group_label>Group 1 - Placebo</arm_group_label>
    <arm_group_label>Group 2 - 250 mg tirasemtiv</arm_group_label>
    <arm_group_label>Group 3 - 375 mg tirasemtiv</arm_group_label>
    <arm_group_label>Group 4 - 500 mg tirasemtiv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of familial or sporadic ALS (defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria) ≤ 24 months prior
             to screening

          -  Upright SVC ≥ 70 % of predicted for age, height and sex

          -  Able to swallow tablets without crushing, and in the opinion of the Investigator, is
             expected to continue to be able to do so during the trial

          -  A caregiver if one is needed

          -  Clinical laboratory findings within the normal range or, if outside the normal range,
             deemed not clinically significant by the Investigator

          -  Male patients must agree for the duration of the study and 10 weeks after the end of
             the study to use a condom during sexual intercourse with female partners who are of
             childbearing potential (i.e., following menarche until post-menopausal if not
             anatomically and physiologically incapable of becoming pregnant) and to have female
             partners use an additional effective means of contraception (e.g., diaphragm plus
             spermicide, or oral contraceptives) or the male patient must agree to abstain from
             sexual intercourse during and for 10 weeks after the end of the study, unless the male
             patient has had a vasectomy and confirmed sperm count is zero

          -  Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of
             childbearing potential, not be breastfeeding, have a negative pregnancy test, have no
             intention to become pregnant during the course of the study, and use effective
             contraceptive drugs or devices while requiring male partner to use a condom for the
             duration of the study and for 10 weeks after the end of the study

          -  Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30
             days prior to screening or have not taken riluzole for at least 30 days prior to
             screening and are willing not to begin riluzole use until they complete study drug
             dosing

        Exclusion Criteria:

          -  At the time of screening, any use of non-invasive positive pressure ventilation
             (NIPPV, e.g. continuous positive airway pressure [CPAP] or bi-level positive airway
             pressure [BiPAP]) for any portion of the day, or mechanical ventilation via
             tracheostomy, or on any form of oxygen supplementation

          -  Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS
             placement during the course of the study

          -  BMI of 20.0 kg/m2 or lower

          -  Unwilling or unable to discontinue tizanidine and theophylline-containing medications
             during study participation

          -  Serum chloride outside the normal reference range

          -  Neurological impairment due to a condition other than ALS, including history of
             transient ischemic attack within the past year

          -  Presence at screening of any medically significant cardiac, pulmonary, GI,
             musculoskeletal, or psychiatric illness that might interfere with the patient's
             ability to comply with study procedures or that might confound the interpretation of
             clinical safety or efficacy data, including, but not limited to:

               1. Poorly controlled hypertension

               2. NYHA Class II or greater congestive heart failure

               3. Chronic obstructive pulmonary disease or asthma requiring daily use
                  bronchodilator medications

               4. GI disorder that might impair absorption of study drug

               5. History of significant liver disease defined by bilirubin &gt; 2 times the upper
                  limit of normal (ULN) or ALT or AST &gt; 3 times the ULN on repeat testing

               6. Poorly controlled diabetes mellitus

               7. History of vertigo within three months of study entry

               8. History of syncope without an explainable or treated cause

               9. History of untreated intracranial aneurysm or poorly controlled seizure disorder

              10. Amputation of a limb

              11. Cognitive impairment, related to ALS or otherwise, sufficient to impair the
                  patient's ability to give informed consent and to understand and/or comply with
                  study procedures

              12. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in
                  situ of the cervix, or squamous cell carcinoma of the skin excised with clean
                  margins) diagnosed and treated within the last two years

              13. Any other condition, impairment or social circumstance that, in the opinion of
                  the Investigator, would render the patient not suitable to participate in the
                  study

              14. Patient judged to be actively suicidal or a suicide risk by the Investigator

          -  Has taken any investigational study drug within 30 days or five half-lives of the
             prior agent, whichever is greater, prior to dosing

          -  Prior participation in any form of stem cell therapy for the treatment of ALS

          -  Previously received tirasemtiv in any previous clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytokinetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital &amp; Medical Center - Barrow Neurology Clinics</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Anschutz Outpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carol and Frank Morsini Center for Advanced Health Care - University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center Dept of Neurology</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Institute Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosciences Institute: Neurology - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Neurological Disorders Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Penn Comprehensive Neuroscience Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virgina Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Department of Neurology</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital, Department of Neurology</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmonton Kaye Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stan Cassidy Centre for Rehabilitation</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B OC7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre, NHI Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Notre-Dame Hospital/CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital R. Salengro, CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hopital Pasteur 2</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bretonneau University Hospital</name>
      <address>
        <city>Tours Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm, Department of Neurology</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School, Department of Neurology</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum, Neurology Department</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre, Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Auxologico Italiano - U.O. Neurologia</name>
      <address>
        <city>Milan</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Neuroscienze &quot;Rita Levi Moltalcini&quot; A.O.U. Citta della Salute e della Scienza di Torino P.O. &quot;Molinette&quot;</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria-Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Rafael</name>
      <address>
        <city>Madrid</city>
        <zip>28016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walton Centre for Neurology and Neurosurgery</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre, Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE59RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2020</results_first_posted>
  <disposition_first_submitted>March 29, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 29, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 2, 2018</disposition_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fast skeletal troponin activator</keyword>
  <keyword>tirasemtiv</keyword>
  <keyword>CK-2017357</keyword>
  <keyword>double-blind</keyword>
  <keyword>randomized</keyword>
  <keyword>placebo-controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02496767/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02496767/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with familial or sporadic amyotrophic lateral sclerosis were enrolled at 79 sites in Belgium, Canada, France, Germany, Great Britain, Ireland, Italy, Netherlands, Portugal, Spain, and the United States. The first patient was screened on 03 September 2015 and the last subject completed on 27 September 2017.</recruitment_details>
      <pre_assignment_details>All enrolled patients began open-label tirasemtiv (250 mg) in a 2-week lead-in phase. Completed patients were randomized (3:2:2:2) to placebo or tirasemtiv (250, 375, or 500 mg) for 48 weeks of double-blind treatment. After which, patients on tirasemtiv were re-randomized (1:1) to placebo or tirasemtiv (current dose) for a 4-week withdrawal phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-label Lead-in: 250 mg Tirasemtiv</title>
          <description>Open-label tirasemiv (125 mg twice daily) for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
          <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
        </group>
        <group group_id="P3">
          <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
          <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
        </group>
        <group group_id="P4">
          <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="P5">
          <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="P6">
          <title>Double-blind, Withdrawal: Placebo</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, patients in the placebo group continued placebo for an additional 4 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Double-blind, Withdrawal: Tirasemtiv to Placebo</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to placebo treatment for 4 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Double-blind, Withdrawal: Tirasemtiv</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to remain on tirasemtiv treatment (at the same dose received at the end of the double-blind, placebo-controlled phase) for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Lead-in Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="744"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="565"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind, Placebo-controlled Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="126"/>
                <participants group_id="P5" count="125"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="66"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind, Withdrawal Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="132"/>
                <participants group_id="P7" count="103"/>
                <participants group_id="P8" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="126"/>
                <participants group_id="P7" count="99"/>
                <participants group_id="P8" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics are provided for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment (totaling 561 patients: 188, 126, 125, and 122 patients in Groups 1, 2, 3, and 4, respectively).</population>
      <group_list>
        <group group_id="B1">
          <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
          <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
        </group>
        <group group_id="B2">
          <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
          <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
        </group>
        <group group_id="B3">
          <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="B4">
          <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="125"/>
            <count group_id="B4" value="122"/>
            <count group_id="B5" value="561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="10.63"/>
                    <measurement group_id="B2" value="57.1" spread="10.20"/>
                    <measurement group_id="B3" value="57.4" spread="9.09"/>
                    <measurement group_id="B4" value="56.0" spread="10.81"/>
                    <measurement group_id="B5" value="56.5" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="541"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Riluzole use at baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)</title>
        <description>SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics [eg, height, age, sex], based on Knudson 83 normative values).</description>
        <time_frame>24 weeks</time_frame>
        <population>The data presented are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)</title>
          <description>SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics [eg, height, age, sex], based on Knudson 83 normative values).</description>
          <population>The data presented are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>% predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.354" spread="1.2270"/>
                    <measurement group_id="O2" value="-12.648" spread="1.5165"/>
                    <measurement group_id="O3" value="-13.742" spread="1.6076"/>
                    <measurement group_id="O4" value="-13.927" spread="1.7213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3782</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>1.707</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9365</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.089</ci_lower_limit>
            <ci_upper_limit>5.503</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7625</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.612</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0245</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.359</ci_lower_limit>
            <ci_upper_limit>4.583</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8394</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.428</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.1081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.711</ci_lower_limit>
            <ci_upper_limit>4.566</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
        <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
          <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="0.258"/>
                    <measurement group_id="O2" value="-1.95" spread="0.320"/>
                    <measurement group_id="O3" value="-2.41" spread="0.340"/>
                    <measurement group_id="O4" value="-2.59" spread="0.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4521</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7120</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.426</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4510</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.439</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
        <description>A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
          <description>A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>change in mega-score/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1501" lower_limit="-0.1729" upper_limit="-0.1272"/>
                    <measurement group_id="O2" value="-0.1512" lower_limit="-0.1794" upper_limit="-0.1230"/>
                    <measurement group_id="O3" value="-0.1434" lower_limit="-0.1742" upper_limit="-0.1126"/>
                    <measurement group_id="O4" value="-0.1413" lower_limit="-0.1730" upper_limit="-0.1095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9505</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0374</ci_lower_limit>
            <ci_upper_limit>0.0351</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7336</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0317</ci_lower_limit>
            <ci_upper_limit>0.0450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6593</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0303</ci_lower_limit>
            <ci_upper_limit>0.0479</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
        <description>This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
          <description>This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2369</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.587</ci_lower_limit>
            <ci_upper_limit>1.141</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9420</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.988</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>1.372</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6853</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.933</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.668</ci_lower_limit>
            <ci_upper_limit>1.304</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
        <description>This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
          <description>This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7667</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.698</ci_lower_limit>
            <ci_upper_limit>1.627</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6619</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.904</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.577</ci_lower_limit>
            <ci_upper_limit>1.419</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5856</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.882</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.561</ci_lower_limit>
            <ci_upper_limit>1.386</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment</title>
        <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment</title>
          <description>The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.39" spread="0.695"/>
                    <measurement group_id="O2" value="-11.39" spread="0.859"/>
                    <measurement group_id="O3" value="-12.19" spread="0.903"/>
                    <measurement group_id="O4" value="-11.99" spread="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9991</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.103</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.17</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4808</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.138</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.04</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6082</p_value>
            <method>Repeated-measures mixed model</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.165</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
        <description>This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.</description>
        <time_frame>48 weeks</time_frame>
        <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
            <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
          </group>
          <group group_id="O2">
            <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
            <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
          </group>
          <group group_id="O3">
            <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
          <group group_id="O4">
            <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
            <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment</title>
          <description>This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.
Note: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.</description>
          <population>The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2602</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.500</ci_lower_limit>
            <ci_upper_limit>1.206</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6748</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.720</ci_lower_limit>
            <ci_upper_limit>1.662</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7694</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.938</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.609</ci_lower_limit>
            <ci_upper_limit>1.443</ci_upper_limit>
            <estimate_desc>Hazard ratio for tirasemtiv vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the first dose of open-label study drug through 28 days after the last dose of study drug.</time_frame>
      <desc>An AE was treatment-emergent if it started or worsened in severity after the first dose of study drug (in either the open-label [OL] or double-blind [DB] phases). The onset date of a TEAE in the OL phase that continued uninterrupted for ≥96 hours in the DB placebo-controlled phase was the date of the first dose of DB study drug.
For patients randomized in the DB withdrawal phase, the onset date was on or before the last dose of study drug in the DB placebo-controlled phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open-label Lead-in: 250 mg Tirasemtiv</title>
          <description>Open-label tirasemiv (125 mg twice daily) for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Double-blind, Placebo-controlled: Group 1 - Placebo</title>
          <description>Day 1 through Week 48: 2 placebo tablets twice daily</description>
        </group>
        <group group_id="E3">
          <title>Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv</title>
          <description>Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM</description>
        </group>
        <group group_id="E4">
          <title>Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="E5">
          <title>Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv</title>
          <description>Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM</description>
        </group>
        <group group_id="E6">
          <title>Double-blind, Withdrawal: Placebo</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, patients in the placebo group continued placebo for an additional 4 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Double-blind, Withdrawal: Tirasemtiv to Placebo</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to placebo treatment for 4 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Double-blind, Withdrawal: Tirasemtiv</title>
          <description>Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to remain on tirasemtiv treatment (at the same dose received at the end of the double-blind, placebo-controlled phase) for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Serratia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Traumatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Genital neoplasm malignant female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Testicular cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="640" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="125" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="123" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="100" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="95" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="45" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="42" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="361" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Parathesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MD Cytokinetics</name_or_title>
      <organization>Cytokinetics, Inc.</organization>
      <phone>650-624-2929</phone>
      <email>medicalaffairs@cytokinetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

